Top 10 Tech Stocks For 2015

The hardware tech wave is surging and investors are quickly paddling out to cash in. Bolt, a Boston based hardware centric seed fund, is among them.

Bolt typically invests $50,000-$100,000 and aims to write larger cheques in the future. But the real value for many first-time or new hardware entrepreneurs is the expertise that the Bolt team brings as a seed fund. The team counts highly experienced mechanical and electrical engineers, manufacturing experts, product and industrial designers as part of their secret sauce to help bring products to market. Some of the team has worked on very commercially successful products, including Pebble watch and the Makerbot 3D printer.

Unlike software start-ups, hardware startups require high tech facilities to bring an idea to life. So beyond the usual office space for minds to meet, Bolt offers machinery and metalworking, electronics, rapid prototyping ��a playground for hardware geeks.

Top 10 Tech Stocks For 2015: Kingdee International Software Group Co Ltd (KGDEF)

Kingdee International Software Group Company Limited is an investment holding company. The principal activities of the Company and its subsidiaries are developing, manufacturing and selling of enterprise management software products and provision of software-related technical services in the People's Republic of China. The Company operates in two segments: enterprise management software business, which is engaged in the sales and implementation of enterprise management software, provision of other related services and sales of hardware related to enterprise management software arrangements, and others, which is engaged in the sales of middleware software business and provision online management services. Its subsidiaries include Beijng Kingdee System Technology Co., Ltd., Kingdee E-commerce Service (Shenzhen) Co., Ltd. and others. Advisors' Opinion:

• [By WWW.MARKETWATCH.COM]

  HONG KONG (MarketWatch) -- Hong Kong stocks trimmed their gains but held to positive territory Wednesday after data showing China's economic growth accelerated to 7.5% in the second quarter, ticking up from a 7.4% gain in the first quarter. The Hang Seng Index (HK:HSI) inched up 0.2%, off slightly from a 0.3% advance ahead of the data, while the Shanghai Composite Index (CN:SHCOMP) dipped 0.1%. Mainland Chinese power companies posted broad gains, with Huadian Power International Corp. (HK:1071) rallying 4.2% after the company forecast its profit for the first six months of the year would jump 55% to 65% from a year earlier. Other stocks in the sector also attracted investors' interest, with Datang International Power Generation Co. (HK:0991) (DIPGF) (CN:601991) and Huaneng Power International Inc. (HK:0902) (HUNGF) (CN:600011) gaining 2.3% and 1.6%, respectively. Menswear maker China Fordoo Holdings Ltd. (HK:2399) rose 1% on its first day of trading. However, most software and gaming companies declined, with Kingdee International Software Group (HK:0268) (KGDEF) losing 1.4%, bigger rival Kingsoft Corp. (HK:3888) (KSFTF) falling 0.9%, and Forgame Holdings L

Top 10 Tech Stocks For 2015: Convergys Corporation (CVG)

Convergys Corporation provides relationship management solutions in North America and internationally. Its Customer Management segment offers agent-assisted, self-service, and intelligent technology care solutions, including customer service, customer retention, sales, technical support, social interaction, collections management, back office, business-to-business, customer experience applied analytics, and intelligent interaction solutions for communications, financial services, technology, retail, healthcare, and government markets. This segment also provides premise-based and hosted automated self-care and technology solutions; speech recognition solutions; and license, professional, consulting and maintenance, and software support services. Convergys Corporation was founded in 1998 and is headquartered in Cincinnati, Ohio.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Convergys (NYSE: CVG) was also up, gaining 12.44 percent to $23.46 after the company announced its plans to acquire Stream Global Services for $820 million in cash. Convergys also reaffirmed its outlook for 2013.

• [By Wallace Witkowski]

  Convergys (CVG) �shares surged 20% to $25 on light volume after the customer management firm announced it will acquire Stream Global Services Inc. for a total enterprise value of $820 million in cash. The acquisition should add about 35 cents a share to Convergys earnings excluding one-time costs, the company said.

Top 5 Defense Companies To Watch For 2015: lime energy co.(LIME)

Lime Energy Co. provides energy engineering, consulting, and implementation solutions to the commercial, industrial, utilities, governmental, and energy services markets in the United States. The company?s energy efficiency solutions enable its clients to reduce energy-related expenditures and the impact of their energy use on the environment. Its services include energy consulting, integrated energy engineering, and multi-measure project development and implementation; mechanical/electrical upgrade services; water conservation; weatherization; and renewables across a range of facilities, including office buildings, manufacturing plants, retail sites, mixed use complexes, and large government sites. The company?s energy consulting and technical services comprise utility program management and implementation, energy project development, energy engineering, consulting, and planning. Lime Energy Co. also provides energy asset development and management services comprising p roject feasibility and technology assessment; sourcing, qualifying, and structuring investment opportunities; project financing; design and construction process management; and asset management. Its customers include commercial and industrial businesses, property owners and managers, utilities, energy service companies, government entities, and educational institutions. The company was formerly known as Electric City Corp. and changed its name to Lime Energy Co. in September 2006. Lime Energy Co. was founded in 1980 and is headquartered in Huntersville, North Carolina.

Advisors' Opinion:

• [By Lauren Pollock]

  Lime Energy Co.(LIME) fired Chief Executive John O’Rourke while simultaneously promoting President and Chief Operating Officer Adam Procell to the top post.

• [By CRWE]

  Lime Energy Co. (NASDAQ:LIME) reported their addition to NSTAR�� Municipal Program, which incentivizes municipalities to implement energy efficiency measures. The pre-selection of energy efficiency contractors is intended to streamline the procurement process for the municipalities that NSTAR currently serves.

Top 10 Tech Stocks For 2015: Synchronoss Technologies Inc.(SNCR)

Synchronoss Technologies, Inc. provides on-demand transaction management solutions primarily in North America. It offers solutions to manage transactions, including device and service procurement, provisioning, activation, intelligent connectivity management, and content synchronization for communications service providers, cable operators/multi-services operators, original equipment manufacturers with embedded connectivity, and e-Tailers/retailers. The company provides ConvergenceNow, ConvergenceNow Plus+, and InterconnectNow platforms that provide on-demand order processing, transaction management, service provisioning, device activation, intelligent connectivity, and content transfer and synchronization through e-commerce, telesales, enterprise, indirect, and other retail outlet channels. It also offers PerformancePartner Portal, a graphical user interface that allows the entry of transaction data into the gateway; Gateway Manager, which offers the capability to fulfill multiple types of transactions; WorkFlow Manager that provides interaction with third-party relationships, as well as enables customers to have a single transaction view, including data from third-party systems; and Visibility Manager, which offers a centralized reporting platform for intelligent analytics around the workflow, transaction management information, historical trending, and mobile reporting for users to receive critical transaction data on mobile devices. In addition, the company provides Content Synchronization Portal that facilitates content migration across devices from different platforms; Device Client, which offers connectivity for activation, connection management, and content migration and synchronization for feature phones, smartphones, computers, and tablets. It sells its products and services through direct sales force and strategic partners. Synchronoss Technologies, Inc. was founded in 2000 and is headquartered in Bridgewater, New Jersey.

Advisors' Opinion:

• [By Lee Jackson]

  Synchronoss Technologies Inc. (NASDAQ: SNCR) may not only beat earnings, but CNBC�� Jim Cramer is touting it as a breakout stock that may be ready to explode for investors. The company provides software-based activation and personal cloud solutions for connected devices. The consensus price target for the stock is $38.

• [By Lee Jackson]

  Synchronoss Technologies Inc. (NASDAQ: SNCR) was added to the Credit Suisse U.S. focus list on Monday. The company trounced earnings expectations and even topped its own sales estimates for the quarter. Cloud services grew 30% from a year ago and now comprise nearly a third of total revenue. Deutsche Bank has a $40 price target, and the consensus number is at $38.

• [By Roberto Pedone]

  Synchronoss Technologies (SNCR) is a provider of on-demand transaction management solutions. This stock closed up 1% at $35.38 in Monday's trading session.

  Monday's Volume: 508,000
  
  Three-Month Average Volume: 284,678
  
  Volume % Change: 80%

  From a technical perspective, SNCR trended up modestly higher here right above some near-term support at $34.27 with above-average volume. This stock has been uptrending strong for the last month and change, with shares moving higher from its low of $26.60 to its recent high of $36.49. During that move, shares of SNCR have been consistently making higher lows and higher highs, which is bullish technical price action. That move has now pushed shares of SNCR within range of triggering a near-term breakout trade. That trade will hit if SNCR manages to take out some near-term overhead resistance levels at $36 to its 52-week high at $36.49 with high volume.

  Traders should now look for long-biased trades in SNCR as long as it's trending above some support at $34 and then once it sustains a move or close above those breakout levels with volume that this near or above 284,678 shares. If that breakout hits soon, then SNCR will set up to enter new 52-week-high territory, which is bullish technical price action. Some possible upside targets off that breakout are $40 to $43.

Top 10 Tech Stocks For 2015: Extreme Networks Inc.(EXTR)

Extreme Networks, Inc., together with its subsidiaries, develops and markets network infrastructure equipment and services to businesses, hospitals, schools, hotels, telecommunications companies, and government agencies. It offers Summit product family of stackable Ethernet switching systems that provide 10 megabit to 40 gigabit connection speeds, various physical presentations, and options to deliver power-over-Ethernet or unpowered standard Ethernet ports; and Black Diamond family of modular Ethernet switching systems, which deliver modular or chassis-based Ethernet connectivity solutions for enterprises, data centers, and service providers. The company also offers SummitWM family of wireless network controllers and associated Altitude access points to enable the deployment of nomadic and mobile converged network applications; and RidgeLine management software system that includes features tailored to data center, campus, and service provider management. It has strategic relationships with Motorola Inc., Netgear, Inc., Ericsson Enterprise AB, and Nokia Siemens Networks. The company sells its products through distributors, resellers, and field sales organizations. It operates in the United States, Canada, Mexico, Japan, Central America, Europe, the Middle East, Africa, South America, and the Asia Pacific. Extreme Networks, Inc. was founded in 1996 and is headquartered in Santa Clara, California.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Extreme Networks (NASDAQ: EXTR) shares tumbled 15.38 percent to $5.96 after the company reported downbeat Q2 results and issued a weak Q3 profit forecast.

• [By Rich Bieglmeier]

  We like to take it one step further than just buying, iStock specifically targets insiders with a history of making the correct call. Extreme Networks Inc. (EXTR) Director, Maury Austin is taking a second bite of the apple.

• [By Jake L'Ecuyer]

  Extreme Networks (NASDAQ: EXTR) shares tumbled 17.33 percent to $5.82 after the company reported downbeat Q2 results and issued a weak Q3 profit forecast.

Top 10 Tech Stocks For 2015: Marketo Inc (MKTO)

Marketo, Inc. (Marketo), incorporated on December 17, 2009, provides cloud-based marketing software platform that enables organizations to engage in modern relationship marketing. The Company�� software platform is designed to enable the execution, management and analytical measurement of marketing activities, helping organizations to acquire new customers. The Company�� platform includes marketing automation, social marketing, sales insight and revenue analytics. Its customer base includes 2,000 customers across a range of industries, including business services, consumer, financial services, healthcare, manufacturing, media, technology and telecommunications. The Company provides its solutions on a subscription basis. Effective December 19, 2013, Marketo Inc acquired Insightera Ltd.

The Company designs, builds and markets a suite of integrated applications to address the needs of modern marketing professionals. The Company�� customers use these applications individually and in combination to streamline and automate marketing processes; develop, retain and extend customer relationships, and measure the positive impact on revenue of marketing programs. Its platform and suite of applications is hosted and delivered over the Web using a cloud-based, or software as a service (SaaS) model, and is built using a multi-tenant architecture. The Company markets and sells its enterprise applications as: Marketo lead management, which includes the core Marketo platform, plus all of the marketing automation capabilities available on the platform; Marketo social marketing, which enables social media campaigns, such as referrals, sweepstakes, and other customer engagement campaigns, and also includes features to add social marketing extensions to traditional marketing campaigns; Marketo sales insight, which provides insights to salespeople about their customers and prospects, and Marketo revenue cycle analytics, which is a suite of analytic tools, analyzers, and ad hoc reporting capabilities taki! ng advantage of its time-series analytics engine.

The Company has built a suite of applications that run on its platform. The applications include marketing automation, social marketing, sales insight and revenue analytics. Marketing automation provides a set of capabilities for marketers to create, automate, and track personalized multi-channel marketing campaigns and relationship-marketing workflows. It includes functionality for marketers to finely segment their prospect and customer database based on collected demographic and behavioral data; generate custom Web pages without programming; send batch and individual personalized marketing messages over email, short message service (SMS) text, and other channels; streamline the entire process of running online (e.g., webinar) and offline (e.g., trade show) marketing events, and to execute multi-step lead nurturing and relationship-marketing campaigns that can run over days, weeks, or months.

Social marketing enables marketers to run social media marketing campaigns, as well as to an increase traditional marketing campaigns with a social marketing aspect in order to amplify marketing messages across social networks. Its solution lets marketers add intelligent social sharing buttons to existing Web content and videos; publish new Facebook pages with the touch of a button; build social engagement applications, such as polls, sweepstakes, and referral offers to engage their audience and promote social cross-posting, and increase existing customer and prospect information with social profiles and sharing behavior.

Sold on a per-seat basis, the Company offers sales insight application to customers utilizing Microsoft dynamics customer relationship management (CRM) or salesforce.com as their CRM system. Revenue Analytics provides a range of ways to help companies understand the correlation between marketing programs and revenue outcomes, and includes: a library of operational reports detailing e-mail and landing page per! formance,! Web activity, and lead performance; intuitive analyzers that show the influence of marketing on individual customer outcomes; analytics that compute and illustrate the impact, effectiveness and return on investment of marketing programs individually and in aggregate, and an ad-hoc report builder for completely customized reports and dashboards.

The Company competes with Act-On, Eloqua, Aprimo, HubSpot, SAS Institute, Unica, ExactTarget, Responsys, Silverpop, Oracle Corporation and SAP AG.

Advisors' Opinion:

• [By gurujx]

  Marketo Inc (MKTO): SVP & CFO Frederick Ball Sold 50,000 Shares

  SVP & CFO of Marketo Inc (MKTO) Frederick Ball sold 50,000 shares on 09/18/2013 at an average price of $33.99.

• [By Lee Jackson]

  The Lazard trading desk said that active traders may want to look at software stocks that still had unusually high short interest. Those included Concur Technologies (NASDAQ: CNQR), Tangoe Inc. (NASDAQ: TNGO), Jive Software (NASDAQ: JIVE), Marketo Inc. (NASDAQ: MKTO), VeriSign Inc. (NASDAQ: VRSN) and VMware Inc. (NYSE: VMW). Stocks with high short interest can explode to the upside if the company gets back on track and short sellers are forced to cover.

Top 10 Tech Stocks For 2015: Pharmacyclics Inc (PCYC)

Pharmacyclics, Inc., incorporated on April 19, 1991, is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of cancer and immune mediated diseases. The Company's clinical development and product candidates are small-molecule enzyme inhibitors designed to target biochemical pathways involved in human diseases. As of June 30, 2011, it had three drug candidates under clinical development and a number of preclinical lead molecules. This includes an inhibitor of Bruton�� tyrosine kinase (Btk) (PCI-32765) in Phase II studies in hematologic malignancies; a Btk inhibitor lead optimization program targeting autoimmune indications, an inhibitor of Factor VIIa (PCI-27483) in a Phase II clinical trial in pancreatic cancer, and a histone deacetylase (HDAC) inhibitor (PCI-24781) in Phase I and II clinical trials in solid tumors and hematological malignancies as of June 30, 2012.

As of June 30, 2012, the Company developed ibrutinib, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a variety of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse B-cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its current or planned Phase Ib/II and Phase III development program. had development programs for B-cell malignancies and autoimmune diseases. For malignant indications it has developed PCI-32765, which has demonstrated clinical activity and tolerability in Phase I and Phase II clinical trials in a range of B-cell malignancies, including chronic lymphocytic leukemia (CLL) and a number of non-Hodgkin�� lymphoma (NHL) subtypes. CLL, mantle cell lymphoma (MCL), follicular lymphoma (FL), diffuse large B cell lymphoma (DLBCL) and multiple myeloma (MM) are specific indications of its Phase II development. It has developed an assay! to measure occupancy of Btk in PBMCs using a cell-permeable fluorescently-labeled derivative of PCI-32765.

Factor VII is an enzyme that becomes activated (FVIIa) by binding to the cell surface protein tissue factor (TF), a protein found in the body that helps to trigger the process of blood clotting in response to injury. TF is over expressed in many cancers including gastric, breast, colon, lung, prostate, ovarian and pancreatic cancers. In these tumors, the FVIIa/TF complex induces intracellular signaling pathways by activating protease activated receptor 2 (PAR-2), another cell-surface protein. This in turn increases the expression of interleukin-8 (IL-8), a protein produced by white blood cells and other immune cells in response to pathogenic stimulation, and vascular endothelial growth factor (VEGF), a signal protein produced by cells that stimulate the growth of blood vessels. Both proteins play an important role in tumor growth and metastases as well as angiogenesis (growth of new blood vessels). FVIIa/TF complex also initiates the coagulation (a process by which blood forms clots) processes implicated in the high incidence of thromboembolic (the process by which the blood clots within a blood vessel) complications seen in patients with TF-expressing cancers. Thromboembolic events are a cause of death in patients with cancer and anticoagulant treatment has been shown to improve survival in a variety of cancers (Klerk et al. JCO. 2005).

PCI-27483 Factor VIIa Inhibitor

The Company�� Factor VIIa inhibitor PCI-27483 is a first-in-human small molecule inhibitor that selectively targets FVIIa. As an inhibitor of FVIIa, PCI-27483 has two potential mechanisms of action: inhibition of intracellular signaling involved in tumor growth and metastases and inhibition of early coagulation processes associated with thromboembolism.

Factor VIIa PCI-27483 Clinical Development Update

A multicenter Phase I/II of PCI-27483 in patients with locally a! dvanced o! r metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). The objectives are to assess the safety of FVIIa Inhibitor PCI-27483 at pharmacologically active dose levels, to assess potential inhibition of tumor progression and to obtain initial information of the effects on the incidence of thromboembolic events. Due to a paradigm shift away from the use of gemcitabine alone for the treatment of pancreatic cancer, enrolling patients in this randomized study has been challenging. PCYC is evaluating other alternatives for development of this agent.

A multicenter Phase I/II of PCI-27483 in patients with locally advanced or metastatic pancreatic cancer that are either receiving or are planned to receive gemcitabine therapy has completed enrollment. The Phase II portion of the study randomized patients to receive either gemcitabine alone or gemcitabine plus PCI-27483 (1.2 mg/kg twice daily). PCI-27483 is covered by United States patents and patent applications and counterpart patents and patent applications in fourteen ex-United States territories, including Europe, Canada, Mexico, Japan, China, India, South Korea, Australia and Brazil.

Advisors' Opinion:

• [By Dan Caplinger]

  Yet J&J isn't satisfied with what it already has. Last week, the company joined with Pharmacyclics (NASDAQ: PCYC  ) to seek approval for their lymphoma drug ibrutinib. J&J will get a 50% share of any profit from the venture, and J&J cited a Piper Jaffray estimate that just one of its indications could produce sales of more than $4 billion.

• [By Sean Williams]

  Biotechnology juggernaut Pharmacyclics (NASDAQ: PCYC  ) -- a company that has returned close to 19,000% since its recession lows -- ignited investor optimism when it and licensing partner Johnson & Johnson (NYSE: JNJ  ) filed a new drug application for ibrutinib. This is truly exciting news, because it marks the first breakthrough therapy drug that's filed for an NDA, and will act the test subject to the rest of the breakthrough therapy designated drugs. Ibrutinib delivered exceptional results in chronic lymphocytic leukemia and mantle cell lymphoma in terms of overall response rate, which should probably net it an approval from the Food and Drug Administration.

Top 10 Tech Stocks For 2015: Provectus Pharmaceuticals Inc (PVCT)

Provectus Pharmaceuticals, Inc., incorporated on May 1, 1978, is a development-stage pharmaceutical company that is primarily engaged in developing ethical pharmaceuticals for oncology and dermatology indications. The Company develops and focuses to license or market and sells its two prescription drug candidates, PV-10 and PH-10. The Company has transferred all its intellectual property related to over the counter (OTC) products and non-core technologies to its subsidiaries and designated, such subsidiaries as non-core to its primary business of developing its oncology and dermatology prescription drug candidates. The Company focuses on developing its prescription drug candidates PV-10 and PH-10. The Company is developing PV-10 for treatment of several life threatening cancers, including metastatic melanoma, liver cancer, and breast cancer. The Company is developing PH-10 to provide minimally invasive treatment of chronic severe skin afflictions such as psoriasis and atopic dermatitis, a type of eczema. All of the Company's prescription drug candidates are in either the pre-clinical or clinical trial stage.

PV-10

As of December 31, 2011, the Company is developing PV-10, a sterile injectible form of rose bengal disodium (Rose Bengal), for direct injection into tumors. Its PV-10 is retained in diseased or damaged tissue but dissipates from healthy tissue. The Company had conducted Phase I and Phase IIstudies of PV-10 for the treatment of metastatic melanoma, and Phase I studies of PV-10 for the treatment of liver and breast cancers.

PH-10

The Company�� prescription drug candidate PH-10 is an aqueous hydrogel formulation of Rose Bengal for topical administration to the skin. The Company is developing PH-10 for the treatment of cutaneous skin disorders, specifically psoriasis and atopic dermatitis. In August 2011, the Company completed follow-up of all Phase IIc patients.

Over-the-Counter Pharmaceuticals

The Company had desi! gnated its subsidiary that holds its OTC products, GloveAid and Pure-ific, Pure-Stick, Pure N Clear as non-core. The Company�� GloveAid is a hand cream with both antiperspirant and antibacterial properties, for the comfort of users��hands during and after the wearing of disposable gloves. Its Pure-ific line of products includes two quick-drying sprays, Pure-ific and Pure-ific Kids, that immediately kill up to 99.9% of germs on skin and prevent regrowth for six hours. Pure-ific products prevent the spread of germs and thus complement its other OTC products designed to treat irritated skin or skin conditions, such as acne, eczema, dandruff and fungal infections. Its Pure-ific sprays have been designed with convenience in mind and are targeted towards mothers, travelers, and anyone concerned about the spread of sickness-causing germs.

The Company�� acne products Pure-Stick and Pure N Clear work by decreasing the production of fats, oils and sweat that create an environment conducive to unchecked growth of bacteria. Secondly, the products also act to reduce the number bacteria already present. The Pure-Stick and Pure N Clear are applied topically to affected areas there are no safety concerns with healthy skin.

Advisors' Opinion:

• [By Jake L'Ecuyer]

  Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.02 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.

• [By Luke Jacobi]

  Provectus Biopharmaceuticals (NYSE: PVCT) was also down, falling 3.38 percent to $3.01, letting out some air after the company's opening on the NYSE Friday.

Top 10 Tech Stocks For 2015: Splunk Inc (SPLK)

Splunk Inc. (Splunk) provides a software platform. Splunk�� software collects and indexes data regardless of format or source, and enables users to search, correlate, analyze, monitor and report on this data, all in real time. Its software is designed to help users in various roles, including information technology (IT) and business professionals, analyze machine data and realize real-time visibility into and about their organization's operations. The core of its software is a machine data engine, comprised of collection, indexing, search and data management capabilities. Its software can collect and index terabytes of information daily, irrespective of format or source. As of January 31, 2012, the Company had approximately 3,700 customers.

The Company�� software enables users to identify problems, get answers and gain new business insights and intelligence from machine data across their globally distributed enterprise all through one platform. Its software contains features and functionality, such as Universally collect, index, store and archive any machine data, from any source, search and investigate, user-friendly interface, knowledge store, monitor and alert, report and analyze, custom dashboards and views, platform extensibility, role-based access and controls.

The Company competes with BMC Software, Inc., CA, Compuware, HP, IBM, Intel, Microsoft Corporation, Quest Software, Adobe Systems, Google, Webtrends, EMC, Oracle and SAP.

Advisors' Opinion:

• [By Matt Jarzemsky]

  Splunk Inc.(SPLK), one of 2012�� hottest initial public offerings, has another stock sale on deck.

  The deal by the data-analysis software maker follows well-received offerings by software makers Workday Inc.(WDAY) and Cvent Inc.(CVT) last week, suggesting investor interest in cloud computing and ��ig data��analysis remain high. Those deals bucked the broader market�� sluggish tone, with indexes little changed out of the gate this year and many strategists predicting muted returns after 2013�� rally.

Top 10 Tech Stocks For 2015: Shanda Games Ltd (GAME)

Shanda Games Limited (Shanda Games), incorporated on June 12, 2008, is engaged in the development and operation of online games and related businesses in the People�� Republic of China. Some of its online games are also Web games, which the Company categorizes as either massively multiplayer online role-playing games (MMORPGs) or advanced casual games, rather than as a separate category of online games. As of February 29, 2012, Shanda Games operated 35 online games. Its game player base, which consisted of 20.4 million average monthly active users and 4.5 million average monthly paying users for the three-month period ended December 31, 2011. In April 2011, the Company acquired a 51.85% interest in a game operating company, which provides services in East Asia.

As of December 31, 2011, the Company owned 149 software copyrights. As of December 31, 2011, it owned or licensed 53 trademarks. As of December 31, 2011, it owned or licensed 329 registered domain names, including its official Website and domain names registered in connection with each of the games the Company offers. As of December 31, 2011, it had 17 patent applications pending with the State Intellectual Property Office of China. The Company operates MMORPGs, advanced casual games and Web games in China. Its MMORPGs are action adventure-based and draw upon themes, such as martial arts adventure, fantasy, strategy and historical events. The Company develops and sources an array of game content through multiple channels, including in-house development, licensing, investment and acquisition, and joint operation. Through these channels, it has built a diversified game portfolio and a game pipeline.

The Company licenses games from international and domestic developers. As of February 29, 2012, 13 of its 35 online games were licensed from third-party developers, including Mir II. It invests in independent game development and operating studios identified by 18 Capital. The Company acquire intellectual property rights t! o online games; equity rights in online game development and operating studios, or an option to acquire equity interests in online game development and operating studios in the future.

The Company operates its business in People's Republic of China, through its wholly owned subsidiaries, which consist of Shengqu Information Technology (Shanghai) Co., Ltd. (Shengqu), Shengji Information Technology (Shanghai) Co., Ltd. (Shengji), Lansha Information Technology (Shanghai) Co., Ltd. (Lansha) and Kuyin Software (Shanghai) Co., Ltd (Kuyin); its variable interest entities and their subsidiaries (VIEs), which consist of Shanghai Hongli Digital Technology Co., Ltd. (Shanghai Hongli) and Shanghai Shulong Technology Development Co., Ltd. (Shanghai Shulong) and their wholly owned subsidiaries, Shanghai Shulong Computer Technology Co., Ltd. (Shulong Computer), Nanjing Shulong Computer Technology Co., Ltd. (Nanjing Shulong), Chengdu Youji Technology Co., Ltd. (Chengdu Youji), Tianjin Youji Technology Co., Ltd. (Tianjin Youji), Chengdu Aurora Technology Development Co., Ltd. (Chengdu Aurora), and Chengdu Simo Technology Co., Ltd. (Chengdu Simo).

The Company competes with Tencent Holdings Limited, NetEase.com, Changyou.com Limited, Perfect World Co., Ltd., Giant Interactive, Kingsoft Corporation Limited, KongZhong Corporation, NetDragon Websoft Inc., Nineyou International Limited, The9 Limited, Activision Blizzard, Inc., Electronic Arts Inc., Zynga Inc., NCSoft Corporation, and Nexon Corporation.

Advisors' Opinion:

• [By Kevin Chen]

  On the heels of a resignation, Shanda Games� (NASDAQ: GAME  ) has appointed a new member to its board of directors.

  The company announced Wednesday that due to personal reasons, Guoxing Jiang had resigned from his spot on the board and also the Audit Committee. Replacing him will be Yong Gui. In the company's press release, Chairman Tianqiao Chen said of the new choice: